Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

20.90 +1.54 (+7.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 295,638
Open 19.40
Bid (Size) 8.430 (200)
Ask (Size) 25.70 (100)
Prev. Close 19.36
Today's Range 18.81 - 21.50
52wk Range 6.875 - 37.27
Shares Outstanding 42,425,071
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
From Neurogene Inc.
Via Business Wire

Performance

YTD
+3.7%
+3.7%
1 Month
+13.0%
+13.0%
3 Month
+4.1%
+4.1%
6 Month
+24.0%
+24.0%
1 Year
+49.7%
+49.7%

More News

Read More
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
Via Stocktwits
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
From Neurogene Inc.
Via Business Wire
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
Via Benzinga
Topics ETFs Stocks
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
Via Benzinga
News headline image
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire

Frequently Asked Questions

Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 20.90
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 03/24/26 04:00 PM ET
What is the market capitalization of Neurogene Inc. - Common Stock?
The market capitalization of Neurogene Inc. - Common Stock is 886.68M
How many shares of Neurogene Inc. - Common Stock are outstanding?
Neurogene Inc. - Common Stock has 887M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.